Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
about
An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and ToxicityDiversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccineCellular and molecular biology of Neisseria meningitidis colonization and invasive diseaseThree doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults.Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines.A naturally derived outer-membrane vesicle vaccine protects against lethal pulmonary Burkholderia pseudomallei infection.FetA Antibodies Induced by an Outer Membrane Vesicle Vaccine Derived from a Serogroup B Meningococcal Isolate with Constitutive FetA Expression.A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.Immunity to Neisseria meningitidis group B in adults despite lack of serum bactericidal antibody.Clonal analysis of Neisseria meningitidis serogroup B strains in South Africa, 2002 to 2006: emergence of new clone ST-4240/6688.Immunogenicity of mycobacterial vesicles in humans: identification of a new tuberculosis antibody biomarker.Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.Genetic distribution of noncapsular meningococcal group B vaccine antigens in Neisseria lactamica.Neisseria lactamica antigens complexed with a novel cationic adjuvantChallenges and progress in the development of a serogroup B meningococcal vaccine.Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.Human Secretory IgM Antibodies Activate Human Complement and Offer Protection at Mucosal Surface.Meningococcal omp85 in detergent-extracted outer membrane vesicle vaccines induces high levels of non-functional antibodies in mice.Neisseria vaccines 2007.Virulence factors of Moraxella catarrhalis outer membrane vesicles are major targets for cross-reactive antibodies and have adapted during evolution.
P2860
Q28607442-65338D3E-43CC-4668-A6FA-27855C0B3293Q33600936-3167BC71-9503-4EB2-AB32-4D4D2A7FC3DDQ33696949-7243102D-CC69-423B-9097-E42901F2B672Q34150340-7D5F2824-EAC6-4FC7-AFD3-81A213F724E1Q34320259-8D431EF2-EA88-4F2C-8589-3A637AB53366Q35375333-06F028A0-4ECB-419A-8440-FA1364D9A9E5Q35806559-ED97A09C-3EF3-4609-9841-62899B38E822Q35949585-F61EB4A8-BC3F-4BD4-9FC0-975A900486A3Q36314090-B23F3573-2A3F-4A9D-9FA8-1CBCBDF4CE89Q36363154-C50CA125-A437-4E22-A8AB-BE12BE842C7DQ36927153-8737FE6C-7C05-4921-AA7D-D553460AB2B3Q37075472-E6939EFA-7A2B-4545-9BE4-F6693A72B673Q37469617-A5C16247-84DF-4C8C-AA86-0444A8A540BEQ37478314-14FEAA0E-5CCF-4DEB-8190-2EB4CB799A33Q37503243-5CAFBFAB-FC4A-40C2-A42E-51AD72A8C71EQ37798011-8D97E2ED-35C6-4BB8-950B-D1FDDC4DC8C0Q38363907-9B72FE9F-9738-4FBC-BE25-2320ACB20F0EQ38606992-90230F17-F4B0-4074-A121-60543D9B1EEFQ40444495-6AFCDF61-586D-412B-B0F1-863B5F1308CFQ42269802-71B6017E-7AE5-476B-8C8A-6465C6F010E6Q46582106-D5BC114C-E4A9-4918-86E0-0526ED1C3746Q54251426-72D12ACB-F144-4D7B-BC02-6F6B6333D42A
P2860
Functional and specific antibody responses in adult volunteers in new zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Functional and specific antibo ...... ter membrane vesicle vaccines.
@ast
Functional and specific antibo ...... ter membrane vesicle vaccines.
@en
type
label
Functional and specific antibo ...... ter membrane vesicle vaccines.
@ast
Functional and specific antibo ...... ter membrane vesicle vaccines.
@en
prefLabel
Functional and specific antibo ...... ter membrane vesicle vaccines.
@ast
Functional and specific antibo ...... ter membrane vesicle vaccines.
@en
P2093
P2860
P356
P1476
Functional and specific antibo ...... ter membrane vesicle vaccines.
@en
P2093
E Rosenqvist
L McCallum
T K Herstad
P2860
P304
P356
10.1128/CVI.00039-07
P577
2007-05-09T00:00:00Z